State of the science in brain tumor classification.

OBJECTIVES To review the incidence of metastatic and primary brain tumors and the most widely used brain tumor classification systems, and to discuss discoveries advancing the understanding, classification, and grading of selected brain tumor histologies. DATA SOURCES Journal articles, text books, epidemiologic and statistical reports. CONCLUSION Recent advances in understanding the molecular biology of brain tumors have shown that molecular and genetic signatures may predict brain tumor behavior and may soon guide tumor classification, diagnosis, and tumor-specific treatment strategies. IMPLICATIONS FOR NURSING PRACTICE Understanding recent advances in the molecular biology of brain tumors is important because these advances may soon guide treatment decisions. New tumor-specific therapeutic opportunities may improve outcomes as well as the care of persons with brain tumors.

[1]  P. Riegman,et al.  Cytogenetic, Molecular Genetic and Pathological Analyses in 126 Meningiomas , 1995, Journal of neuropathology and experimental neurology.

[2]  F. Davis,et al.  Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. , 2001, Neuro-oncology.

[3]  J. Rutka,et al.  Transcriptional profiling of medulloblastoma in children. , 2003, Journal of neurosurgery.

[4]  R. Weller,et al.  International Histological Classification of Tumours , 1981 .

[5]  D. Graham,et al.  Atlas of Tumor Pathology: Tumors of the central nervous system , 1995 .

[6]  L. J. Rubinstein,et al.  Tumors of the central nervous system , 1972 .

[7]  Harlan I. Firminger,et al.  Atlas of tumor pathology , 1954 .

[8]  D. Bigner,et al.  Cytogenetics of human brain tumors. , 1990, Cancer genetics and cytogenetics.

[9]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[10]  Roy A. Patcheil.  Metastatic brain tumors. , 1995 .

[11]  K. Plate,et al.  p53 Mutations versus EGF Receptor Expression in Giant Cell Glioblastomas , 1997, Journal of neuropathology and experimental neurology.

[12]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[13]  R. Cawthon,et al.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. , 1992, Cancer research.

[14]  R. Perry,et al.  Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. , 1995, British Journal of Cancer.

[15]  D. Louis,et al.  Molecular pathways in the formation of gliomas , 1995, Glia.

[16]  N. Ringertz.  Grading of gliomas. , 2009 .

[17]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.

[18]  I. Petersen,et al.  Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. , 1992, Cancer research.

[19]  P. Bailey,et al.  A classification of the tumors of the glioma group on a histogenetic basis with a correlated study of prognosis , 1970 .

[20]  P. Kleihues,et al.  Genetic alterations associated with the evolution and progression of astrocytic brain tumours , 2004, Virchows Archiv.

[21]  E. Berg,et al.  World Health Organization Classification of Tumours , 2002 .

[22]  A. Sloan,et al.  Relative survival rates and patterns of diagnosis analyzed by time period for individuals with primary malignant brain tumor, 1973-1997. , 2003, Journal of neurosurgery.

[23]  G. Fulci,et al.  p53 and Brain Tumors: From Gene Mutations to Gene Therapy , 1998, Brain pathology.

[24]  Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994. , 1999, Neuro-oncology.

[25]  R. McLendon,et al.  Chromosomal characteristics of childhood brain tumors. , 1997, Cancer genetics and cytogenetics.

[26]  F. Davis,et al.  Trends in incidence of primary brain tumors in the United States, 1985-1994. , 2001, Neuro-oncology.

[27]  Dorothy S. Russell,et al.  Pathology of Tumours of the Nervous System , 1972 .

[28]  O. G. Dodge,et al.  Histological Typing of tumours of the Central Nervous System , 1981, British Journal of Cancer.

[29]  L. Larocca,et al.  The molecular and phenotypic profile of primary central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-related B cells. , 1998, Blood.

[30]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[31]  D. Louis.  A Molecular Genetic Model of Astrocytoma Histopathology , 1997, Brain pathology.

[32]  Y Sawamura,et al.  Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression. , 1999, Neuro-oncology.

[33]  Y. Yonekawa,et al.  Overexpression of the EGF Receptor and p53 Mutations are Mutually Exclusive in the Evolution of Primary and Secondary Glioblastomas , 1996 .

[34]  J. Rey,et al.  NF2 gene mutations and allelic status of 1p, 14q and 22q in sporadic meningiomas , 1999, Oncogene.

[35]  J. Armitage,et al.  Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  D. Louis,et al.  Molecular Genetic Evidence for Subtypes of Oligoastrocytomas , 1997, Journal of neuropathology and experimental neurology.